06 May Novel 68Ga-PSMA-ligand Improves PET/CT Detection of Recurrent Prostate Cancer
Medical Research: What is the background for this study? What are the main findings?
Dr. Eiber: The background of the study is the investigation of a novel 68Ga-PSMA ligand using PET/CT in the workup of patients with recurrent prostate cancer after radical prostatectomy. Hereby, we found substantial higher detection rate compared to other methods. In total 222 (89.5%) patients showed pathological findings in 68Ga-PSMA-ligand PET/CT. Stratified by PSA-level the detection rates were 96.8%,93.0%,72.7% and 57.9% of ≥2,1-<2, 0.5-<1 and 0.2-<0.5ng/mL, respectively.
Medical Research: What should clinicians and patients take away from your report?
Dr. Eiber: For clinicians and patients the main point includes that 68Ga-PSMA PET/CT enables detection and localization of recurrent prostate cancer at a higher efficiency than reported for other tracers/imaging modalities. Most importantly, it reveals a high number of positive findings in the clinically important range of low PSA-values (<0.5ng/mL), which in many cases can substantially influence the further clinical management.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Eiber: Further research in that area should focus on the use of 68Ga-PSMA-ligand PET imaging in the area of primary prostate cancer. Here, a direct comparison between the imaging finding and postoperative histopathology allows a better determination of the potential of this tracer as well as its usefulness in primary staging. In the setting of increased PSA-value with prior negative biopsy the use of 68Ga-PSMA PET/MR imaging combining the excellent morphological detail, multiparametric functional information in MR and molecular information in PET could possible improve the detection of primary prostate cancer
Eiber, T. Maurer, M. Souvatzoglou, A. J. Beer, A. Ruffani, B. Haller, F.-P. Graner, H. Kubler, U. Haberhorn, M. Eisenhut, H.-J. Wester, J. E. Gschwend, M. Schwaiger. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. Journal of Nuclear Medicine, 2015; 56 (5): 668 DOI: 10.2967/jnumed.115.154153
MedicalResearch.com Interview with: Matthias Eiber, MD (2015). Tracer Improves PET/CT Detection of Recurrent Prostate Cancer